Patents Represented by Attorney Shawn P. Foley
-
Patent number: 6020153Abstract: The invention relates to murine/human chimeric monoclonal antibodies with high specificity to and affinity for human carcinoembryonic antigen (CEA), derivatives thereof, processes for the preparation of these antibodies and their derivatives, DNAs coding for heavy and light chains of these antibodies, processes for the preparation of said DNAs, mammalian cell lines that produce and secrete the antibodies and processes for the preparation of said cell lines. The chimeric antibodies and their derivatives are used for clinical purposes in vitro and in vivo, especially for the diagnosis of cancer, for localization and in vivo imaging of tumors, for therapy, e.g. site-directed delivery of cytotoxins, and similar purposes. The invention also concerns test kits and pharmaceutical compositions containing said chimeric monoclonal antibodies and/or derivatives thereof.Type: GrantFiled: September 16, 1994Date of Patent: February 1, 2000Assignee: Ciba-Geigy CorporationInventors: Norman Hardman, Laura Lee Gill, Ronald F. J. de Winter, Kathrin Wagner, Christoph Heusser
-
Patent number: 5646037Abstract: The invention relates to the field of genetic engineering and provides novel hybrid vectors based on the yeast two micron plasmid. The novel hybrid vectors are stably maintained in the cell during proliferation and are useful for the expression of heterologous genes in yeast in large scale batch and particularly in continuous culture.Type: GrantFiled: November 2, 1994Date of Patent: July 8, 1997Assignee: Ciba-Geigy CorporationInventor: Frank Buxton
-
Patent number: 5290926Abstract: The present invention comprises cDNA coding for histidinol dehydrogenase from plants, the final step in histidine biosynthesis. The invention also comprises a novel method of purifying histidinol dehydrogenase from plants to essential honogeneity, the purified histidinol dehydrogenase, an assay for identifying inhibitors of histidinol dehydrogenase, an assay to identify mutants of histidinol dehydrogenase that are not inhibited by inhibitors of wild-type histidinol dehydrogenase, the inhibitors so identified as well as herbicide compositions containing them, the non-inhibited mutants of histidinol dehydrogenase, transgenic crop plants containing the non-inhibited mutants of histidinol dehydrogenase, and methods of treating weeds utilizing the application of histidinol dehydrogenase inhibitors to the transgenic crops containing the non-inhibited mutants of histidinol dehydrogenase.Type: GrantFiled: September 14, 1990Date of Patent: March 1, 1994Assignee: Ciba-Geigy CorporationInventors: Alfred Scheidegger, Eric R. Ward, John A. Ryals, Atsuko Nagai-Hayashi
-
Patent number: 5268296Abstract: Novel polypeptides, designated hirullins, have a strong antithrombic activity and can therefore be used for the therapy and prophylaxis of thromboses. Said compounds are isolated from the leech Hirudinaria manillensis or are produced by conventional peptide synthesis or by recombinant DNA techniques. DNA sequences encoding hirullins P6 and P18 are supplied, hybrid vectors and transformed microorganisms for recombinant hirullin production are supplied.Type: GrantFiled: February 21, 1992Date of Patent: December 7, 1993Assignees: Ciba-Geigy Corporation, UCP Gen-Pharma, AGInventors: Reinhard Maschler, Verena Steiner, Markus G. Grutter
-
Patent number: 5248607Abstract: The present invention provides a novel method to purify green-plant phytochrome; the production of hybridoma cell lines secreting monoclonal antibodies specific for green-plant phytochrome and that do not cross-react significantly with etiolated-plant phytochrome; a partial amino acid sequence for an immunoaffinity-purified green-plant phytochrome; oligonucleotide probes for cloning green-phytochrome genes from plant genomic DNA and cDNA libraries; and cloned green-phytochrome genes and cDNA.Type: GrantFiled: October 27, 1988Date of Patent: September 28, 1993Assignee: Ciba-Geigy CorporationInventors: Marie-Michele Cordonnier, Lee Pratt, Sandy Stewart, Alice Montoya
-
Patent number: 5242819Abstract: Novel single-chain hybrid plasminogen activators having an amino acid sequence composed of at least two subsequences corresponding in amino acid identity and number to subsequences of human t-PA and of human u-PA, and mutants thereof in which at least one of the N-glycosylation sites is modified such that glycosylation cannot take place at these sites exhibit valuable pharmacological properties. The hybrid plasminogen activators are produced by recombinant DNA technology.Type: GrantFiled: December 13, 1991Date of Patent: September 7, 1993Assignee: Ciba-Geigy CorporationInventors: Bhanu Rajput, Bhabatosh Chaudhuri, Fredericus A. M. Asselbergs, Bernd Meyhack, Jutta Heim, Jan van Oostrum, Sefik Alkan
-
Patent number: 5231019Abstract: A novel process for the direct transfer of foreign genes to plant genomes is described. The novel process comprises placing a gene under the control of plant expression signals and transferring it, by contact with protoplasts without the aid of natural systems for infecting plants, directly to plant cells from which genetically transformed plants can subsequently be derived.Type: GrantFiled: February 23, 1990Date of Patent: July 27, 1993Assignee: Ciba-Geigy CorporationInventors: Jerzy Paszkowski, Ingo Potrykus, Barbara Hohn, Raymond D. Shillito, Thomas Hohn, Michael W. Saul, Vaclav Mandak
-
Patent number: 5217871Abstract: The invention relates to monoclonal antibodies that react specifically with members of the genus Leptosphaeria and hybridomas that produce such antibodies. The invention is further directed to a method for making a hybridoma cell line that produces monoclonal antibodies that react specifically with Leptosphaeria nodorum, and a method of obtaining monoclonal antibodies therefrom. Methods and kits for diagnosing Leptosphaeria infections in plant material using such monoclonal antibodies are also within the scope of the invention.Type: GrantFiled: August 21, 1990Date of Patent: June 8, 1993Assignee: Ciba-Geigy CorporationInventors: Frank P. Petersen, Mark D. Clymer, Sally A. Miller, James H. Rittenburg, G. David Grothaus
-
Patent number: 5196316Abstract: The invention concerns a peptidylhydroxyglycine N-C lyase (PHL) catalyzing the reactionR-GlyOH.fwdarw.R-NH.sub.2wherein R represents a peptide residue, and GlyOH represents an .alpha.-hydroxyglycine residue linked to the C-terminus of said peptide R by an amide bond, a recombinant DNA molecule coding for a PHL, a method for the preparation of such a recombinant DNA molecule, processes for the preparation of PHL from a natural source or by means of the said recombinant DNA molecule, and the use of PHL for the preparation of an amidated peptide R-NH.sub.2.Type: GrantFiled: May 30, 1991Date of Patent: March 23, 1993Assignee: Japat Ltd.Inventors: Yasuno Iwasaki, Yoshiki Nishikawa
-
Patent number: 5180667Abstract: DNA encoding novel eglin mutants that differ from the natural eglins B and C by the replacement of amino acids in the region of the active center (amino acid 45) by other amino acids are provided. The mutants, which are produced by recombinant genetic engineering, have valuable pharmacological properties.Type: GrantFiled: October 11, 1991Date of Patent: January 19, 1993Assignees: Ciba-Geigy Corporation, UCP Gen-Pharma, AGInventors: Markus G. Grutter, Dirk Heinz, Manfred Liersch
-
Patent number: 5095139Abstract: Rhizocticines of the formula ##STR1## in which X represents hydrogen or a hydrophobic amino acid radical and Y represents a basic amino acid radical, the C2 atoms of the amino acid radicals having the L-configuration, and protected derivatives and salts thereof.The compounds are obtained from culture broths of Bacillus subtilis or synthetically and have especially fungicidal action.Type: GrantFiled: April 26, 1990Date of Patent: March 10, 1992Assignee: Ciba-Geigy CorporationInventors: Wolfgang Loeffler, Martin Kugler, Gunther Jung, Armin Kern, Claudius Rapp
-
Patent number: 5079229Abstract: Novel elgin mutants that differ from the natural eglins B and C by the replacement of one, two or three amino acids in the region of the active center (amino acids 45 and 46, Leu-Asp) by other amino acids are provided. The mutants, which can be produced by recombinant genetic engineering, have valuable pharmacological properties.Type: GrantFiled: March 7, 1989Date of Patent: January 7, 1992Assignee: Ciba-Geigy CorporationInventors: Markus G. Grutter, Dirk Heinz, Manfred Liersch